Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE vs REMODULIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pentazocine is a mixed agonist-antagonist opioid that binds to mu-opioid receptors (partial agonist) and kappa-opioid receptors (agonist), producing analgesia. Naloxone is a pure opioid antagonist that competitively blocks mu, kappa, and delta receptors; when administered orally, naloxone undergoes extensive first-pass metabolism, reducing systemic absorption and primarily blocking the effects of pentazocine if the combination is misused parenterally.
Treprostinil is a synthetic prostacyclin analog that directly vasodilates pulmonary and systemic arterial beds, inhibits platelet aggregation, and suppresses smooth muscle proliferation.
Moderate to severe pain relief; combinations are used to reduce abuse potential.
Pulmonary arterial hypertension (WHO Group I) to improve exercise capacity and reduce symptoms,Off-label: Severe Raynaud's phenomenon, digital ischemia, and salvage therapy for PAH in patients failing other prostacyclins
Oral: One tablet (naloxone 0.5 mg / pentazocine 50 mg) every 3-4 hours as needed for pain; maximum 12 tablets daily.
Continuous subcutaneous infusion: Initially 1.25 ng/kg/min; increase by 1.25 ng/kg/min every week for first 4 weeks, then by 2.5 ng/kg/min every week as tolerated. Intravenous infusion: same dosing.
Pentazocine has an elimination half-life of 2-3 hours in healthy adults, which may be prolonged in patients with hepatic impairment. Naloxone has a terminal half-life of 0.5-1.5 hours in adults, with a rapid decline in plasma levels; the short half-life limits its duration of opioid antagonism.
Terminal elimination half-life is approximately 4 hours (range 2-7 hours) following continuous subcutaneous infusion; clinical context: requires continuous infusion due to short half-life.
Pentazocine is metabolized primarily by hepatic conjugation (glucuronidation) and oxidation via CYP2C19 and CYP2D6; naloxone is extensively metabolized by the liver, primarily via glucuronidation (UGT2B7).
Hepatic metabolism via CYP2C8 and CYP2C9 (major), with minor contributions from CYP2C19 and CYP2D6; major metabolite is a glucuronide conjugate.
Pentazocine is primarily metabolized in the liver and excreted in urine as conjugates of glucuronide and sulfate, with about 60% of a dose excreted renally within 24 hours as metabolites and unchanged drug (less than 5% unchanged). Naloxone undergoes extensive hepatic metabolism to naloxone-3-glucuronide, which is excreted renally; approximately 50% of a dose is excreted as conjugates in urine within 6 hours.
Renal: 20-30% as unchanged drug; fecal: 70-80% as metabolites (via biliary elimination).
Pentazocine: Approximately 35-65% bound to plasma proteins (mainly albumin). Naloxone: Approximately 32-45% bound to plasma proteins (mainly albumin).
Approximately 58% bound to human plasma proteins, primarily to albumin.
Pentazocine: Vd ~2-3 L/kg, indicating extensive tissue distribution. Naloxone: Vd ~2-3 L/kg, also indicating wide distribution.
Volume of distribution (Vd) is 1.3 L/kg (range 0.8-2.0 L/kg); clinical meaning: extensive distribution into tissues, exceeding total body water.
Oral pentazocine: 20-30% due to first-pass metabolism. Intramuscular pentazocine: 100%. Subcutaneous pentazocine: 100%. Oral naloxone: <2% due to extensive first-pass metabolism. Intramuscular and subcutaneous naloxone: 100%. Intravenous: 100% for both.
Subcutaneous: approximately 100% bioavailable compared to intravenous; oral: negligible (not administered orally).
GFR 30-50 m L/min: Administer every 6 hours; GFR 10-29 m L/min: Administer every 8-12 hours; GFR <10 m L/min: Administer every 12 hours or consider alternative.
No dosage adjustment required for renal impairment.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 50% or extend interval; Child-Pugh Class C: Avoid use.
Mild to moderate hepatic impairment (Child-Pugh class A or B): no adjustment. Severe hepatic impairment (Child-Pugh class C): contraindicated.
Not recommended for children under 12 years. For older children (≥12 years): Pentazocine 50 mg (with naloxone 0.5 mg) orally every 3-4 hours as needed; maximum 6 tablets daily.
Not established; safety and efficacy in pediatric patients have not been studied.
Initiate with half the usual adult dose (one-half tablet) and titrate carefully due to increased sensitivity and risk of respiratory depression.
No specific dose adjustment recommended; use with caution due to age-related renal/hepatic decline.
Risk of respiratory depression, particularly in elderly, cachectic, or debilitated patients; risk of addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of life-threatening respiratory depression when used with benzodiazepines or other CNS depressants.
None. However, infusion site reactions (pain, erythema, induration) and risk of catheter-related bloodstream infections are significant concerns.
Respiratory depression; hypotension; increased intracranial pressure; seizure risk (pentazocine); opioid-induced hyperalgesia; adrenal insufficiency; severe hypotension; interaction with MAOIs; risk of dependence and withdrawal; gastrointestinal obstruction; impaired renal or hepatic function; head injury.
Sudden discontinuation may worsen PAH; taper if possible.,Infusion site reactions are common; avoid extravasation.,Risk of bleeding due to antiplatelet effects; use with caution in patients with peptic ulcer disease or on anticoagulants.,Hepatic impairment may increase exposure; dosage adjustment may be needed.,May cause systemic hypotension; monitor blood pressure.
Hypersensitivity to pentazocine or naloxone; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; known or suspected paralytic ileus; patients receiving MAOIs or within 14 days.
Known hypersensitivity to treprostinil or any excipient,Patients with severe hepatic impairment (Child-Pugh class C) due to lack of safety data
No specific food interactions are reported for this combination. However, grapefruit juice may theoretically affect metabolism via CYP3A4 (pentazocine is metabolized by CYP3A4), but clinical significance is unknown. Advise patients to maintain a consistent diet.
There are no known food interactions with treprostinil. However, patients should maintain a balanced diet as part of overall PAH management. Grapefruit juice has not been reported to interact, but always consult with a healthcare provider.
Pentazocine crosses the placenta; naloxone has limited placental transfer. No well-controlled human studies. First trimester: Risk cannot be excluded; avoid if possible. Second/Third trimester: Chronic use may cause fetal dependence; neonatal withdrawal syndrome reported. High doses near term may cause neonatal respiratory depression.
Teriprostinil (REMODULIN) is contraindicated in pregnancy due to teratogenic effects in animal studies (increased cardiovascular and skeletal malformations). There are no adequate human data; however, based on animal findings, fetal risk cannot be excluded, particularly in the first trimester. In later trimesters, risks include potential fetal harm from maternal hypotension and hypoxia.
Pentazocine is excreted in breast milk in small amounts (estimated relative infant dose <3%). Naloxone is poorly bioavailable orally. Generally considered compatible with breastfeeding; monitor infant for sedation or poor feeding. M/P ratio for pentazocine is approximately 1.0.
It is unknown if teriprostinil is excreted in human milk. M/P ratio not established. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for at least 48 hours after the last dose.
No established dose adjustments for pregnancy; however, pharmacokinetic changes (increased volume of distribution, enhanced clearance) may require higher or more frequent doses of pentazocine for adequate analgesia. Use lowest effective dose and shortest duration.
Pregnancy is a contraindication; thus no dose adjustments are applicable. However, if used in exceptional circumstances, plasma volume expansion in pregnancy may alter drug distribution, but specific dose recommendations are lacking. Use is not recommended.
Naloxone in this fixed-dose combination is included to deter opioid abuse by reversing euphoria. The pentazocine component is a mixed agonist-antagonist opioid; naloxone has poor oral bioavailability but becomes active parenterally, precipitating withdrawal in opioid-dependent individuals. Use with caution in patients with impaired renal or hepatic function. Monitor for respiratory depression, especially in opioid-naive patients, as pentazocine alone can cause respiratory depression.
REMODULIN (treprostinil) is a prostacyclin analog used for pulmonary arterial hypertension (PAH). Avoid abrupt discontinuation due to risk of rebound pulmonary hypertension. Monitor for infusion site reactions and bleeding risk due to antiplatelet effects. Dose titration should be guided by PAH symptoms and side effects. Use with caution in patients with hepatic impairment.
Take exactly as prescribed; do not crush or inject tablets, as injected naloxone can cause severe withdrawal in opioid-dependent individuals.,This medication contains naloxone to discourage misuse; injection will cause withdrawal symptoms.,Report any signs of withdrawal (e.g., nausea, vomiting, sweating, agitation) or breathing difficulty.,Avoid alcohol and other central nervous system depressants as they increase risk of respiratory depression.,Do not use with other opioids unless directed, as effects are unpredictable.,Keep out of reach of children; accidental ingestion may cause severe respiratory depression.
Do not stop taking this medication suddenly; sudden cessation may cause worsening of symptoms.,Report any signs of bleeding (e.g., easy bruising, nosebleeds, blood in urine or stool) to your healthcare provider.,If using subcutaneous infusion, rotate injection sites to prevent site reactions and infection.,Store medication as directed; do not freeze or expose to excessive heat.,Avoid activities that increase bleeding risk, such as contact sports, until you discuss with your doctor.
"Cobicistat is a potent CYP3A4 inhibitor used to boost the pharmacokinetics of antiretroviral agents like atazanavir and darunavir. Naloxone primarily undergoes glucuronidation via UGT1A6 and UGT2B7, with minor CYP3A4 metabolism. Concomitant use with Cobicistat may modestly increase naloxone exposure due to CYP3A4 inhibition, but this is unlikely to be clinically significant given naloxone's wide therapeutic index and short half-life."
"Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is primarily metabolized by cytochrome P450 (CYP) 1A2 and 2D6. Naloxone, an opioid antagonist, is reported to inhibit CYP1A2, potentially decreasing the clearance of fluvoxamine. This interaction may lead to increased fluvoxamine plasma concentrations, elevating the risk of serotonin syndrome, QT prolongation, and other dose-dependent adverse effects, especially in patients receiving high doses or those with hepatic impairment."
"Naloxone, an opioid receptor antagonist, may inhibit the cytochrome P450 isoenzyme CYP3A4, which is responsible for the metabolism of ivacaftor. Concomitant administration can lead to reduced clearance of ivacaftor, resulting in elevated serum concentrations. This increase may potentiate the therapeutic effects and adverse reactions of ivacaftor, such as hepatotoxicity and QT prolongation."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE vs REMODULIN, answered by our medical review team.
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Pentazocine is a mixed agonist-antagonist opioid that binds to mu-opioid receptors (partial agonist) and kappa-opioid receptors (agonist), producing analgesia. Naloxone is a pure opioid antagonist that competitively blocks mu, kappa, and delta receptors; when administered orally, naloxone undergoes extensive first-pass metabolism, reducing systemic absorption and primarily blocking the effects of pentazocine if the combination is misused parenterally.. REMODULIN is a Prostacyclin Vasodilator that works by Treprostinil is a synthetic prostacyclin analog that directly vasodilates pulmonary and systemic arterial beds, inhibits platelet aggregation, and suppresses smooth muscle proliferation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE and REMODULIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is: Oral: One tablet (naloxone 0.5 mg / pentazocine 50 mg) every 3-4 hours as needed for pain; maximum 12 tablets daily.. The standard adult dose of REMODULIN is: Continuous subcutaneous infusion: Initially 1.25 ng/kg/min; increase by 1.25 ng/kg/min every week for first 4 weeks, then by 2.5 ng/kg/min every week as tolerated. Intravenous infusion: same dosing.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE and REMODULIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is classified as Category A/B. Pentazocine crosses the placenta; naloxone has limited placental transfer. No well-controlled human studies. First trimester: Risk cannot be excluded; avoid if possible. Second/Thi. REMODULIN is classified as Category C. Teriprostinil (REMODULIN) is contraindicated in pregnancy due to teratogenic effects in animal studies (increased cardiovascular and skeletal malformations). There are no adequate . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.